Range Impact promotes Patricia Missal to CFO, plans divestiture of Graphium subsidiary

RANGE IMPACT, INC.

Patricia Missal promoted from Controller to CFO, replacing Richard McKilligan, effective April 25, 2024.
Missal receives annual base salary of $225,000 and options to purchase 250,000 shares with vesting terms.
Dr. Brandon Zipp and Richard McKilligan transition to Graphium Biosciences roles for proposed divestiture.
Range Impact engaged First Liberties Financial in Dec. 2023 to help raise capital for Graphium divestiture.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Richard McKilligan

Chief Financial Officer of Graphium Biosciences, Inc.

RNGE · RANGE IMPACT, INC.

Effective: 2024-04-25
Successor: Patricia Missal
Filed: April 26, 2024, 7:59 PM ET

Mr. McKilligan will remain as Chief Financial Officer of Graphium Biosciences, Inc., a wholly-owned subsidiary of the Company (“Graphium”).

Appointed

Patricia Missal

Chief Financial Officer

RNGE · RANGE IMPACT, INC.

Effective: 2024-04-25
Filed: April 26, 2024, 7:59 PM ET

On April 25, 2024, the Board of Directors of Range Impact, Inc. (the “Company”) elected Patricia Missal as Chief Financial Officer, replacing Richard McKilligan who had previously served as the Company’s Chief Financial Officer, Counsel and Secretary.

Role change

Dr. Brandon Zipp

Chief Science Officer of Graphium

RNGE · RANGE IMPACT, INC.

Effective: 2024-04-25
Filed: April 26, 2024, 7:59 PM ET

Dr. Brandon Zipp, who had served as the Company’s Chief Science Officer, will, effective April 25, 2024, serve exclusively as the Chief Science Officer of Graphium.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard McKilligan changed role as Chief Financial Officer of Graphium Biosciences, Inc. at RANGE IMPACT, INC..

Action: will remain as
Role: Chief Financial Officer of Graphium Biosciences, Inc.

Exact text from the filing

Mr. McKilligan will remain as Chief Financial Officer of Graphium Biosciences, Inc., a wholly-owned subsidiary of the Company (“Graphium”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Patricia Missal was elected as Chief Financial Officer at RANGE IMPACT, INC..

Action: elected
Role: Chief Financial Officer

Exact text from the filing

On April 25, 2024, the Board of Directors of Range Impact, Inc. (the “Company”) elected Patricia Missal as Chief Financial Officer, replacing Richard McKilligan who had previously served as the Company’s Chief Financial Officer, Counsel and Secretary.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Brandon Zipp changed role as Chief Science Officer of Graphium at RANGE IMPACT, INC..

Action: serve exclusively as
Role: Chief Science Officer of Graphium

Exact text from the filing

Dr. Brandon Zipp, who had served as the Company’s Chief Science Officer, will, effective April 25, 2024, serve exclusively as the Chief Science Officer of Graphium.

View on SEC.gov

RANGE IMPACT, INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-016075

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.